C22orf39

Across TCGA pan-cancer cohorts, C22orf39 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C22orf39 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher C22orf39 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated C22orf39 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where C22orf39 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.616	0.896	.005	22	view →
LSCC	OS	Quartile	All	0.473	0.955	.008	3	view →
LUAD	DFS	Median	All	1.000	0.741	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

C22orf39–CCRCC (DFS)

Open the CCRCC breakdown →